Praziquantel, praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of schistosomiasis
- Conditions
- Infection with Schistosoma spp.Infections and InfestationsSchistosomiasis [bilharziasis]
- Registration Number
- ISRCTN00393859
- Lead Sponsor
- Swiss Tropical and Public Health Institute (Switzerland)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 150
1. Patients (male and female school children older than 8 years) infected with Schistosoma mansoni and S. haematobium, as assessed by the presence of eggs in the urine or stool
2. Weight of patient greater than 25 kg
3. Able and willing to be examined by a study physician at the beginning of the study and at the end of study (3 weeks post-treatment and 2 - 3 months post-treatment)
4. Able and willing to provide multiple stool and urine samples at the beginning and end of study
5. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment
6. Absence of psychiatric and neurological disorders
7. No known or reported hypersensitivity to mefloquine, praziquantel and/or artesunate
8. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease
9. Signed written informed consent sheet
10. For females aged 12 years and above, not pregnant in the first trimester, as assessed by a pregnancy test, upon initial clinical assessment
1. Pregnancy first trimester
2. Presence of any abnormal medical condition, judged by the study physician
3. History of acute or severe chronic disease
4. Known or reported psychiatric or neurological disorders
5. Use of antimalarial or anthelminthic drug within the past month
6. Attending other clinical trials during the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method